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Duchenne Muscular Dystrophy (DMD) is a fatal condition occurring in approximately 1 
in 3500 male births and is due to the lack of a protein called dystrophin.  Initially DMD 
was considered a skeletal myopathy, but the pathology and consequences of 
cardiomyopathy are being increasingly recognised. Fibrosis, resulting from continual 
cycles of degeneration of the muscle tissues followed by inadequate regeneration of the 
muscles, is progressive in both cardiac and skeletal dystrophic muscle. In the heart 
fibrosis interferes with contractility and rhythm whereas it affects contractile function and 
causes contractures in skeletal muscles.  This study utilised the mdx mouse which 
exhibits a pathological loss of muscle fibres and fibrosis characteristic of DMD, to 
examine a range of mechanisms that can influence muscle function and fibrosis. 
 
Ageing and workload both appear to contribute to the development of dystrophic features 
in cardiac and skeletal muscle of the mdx mouse.  Therefore the effect of eccentric 
exercise on cardiac and skeletal muscle was examined in older mdx mice. Mice ran in 30 
minute sessions for five months, 5 days per week.  Downhill treadmill running did not 
exacerbate the contractile function or fibrosis of the mdx heart or the EDL, SOL or 
diaphragm muscles suggesting that cytokines influence function and fibrosis to a greater 
extent than workload alone.   
 
The role of the cytokine TGF-β was examined by treating mdx mice with the TGF-β 
antagonist pirfenidone at 0.4, 0.8 or 1.2 % in drinking water for six months. Pirfenidone 
improved cardiac contractility (P<0.01) and coronary flow (P<0.05), to levels 
comparable to control mice, despite no reduction in cardiac fibrosis.  Pirfenidone did not 
reduce fibrosis or improve function in skeletal muscle.  
 
A deficiency of neuronal nitric oxide synthase (nNOS) in DMD and mdx mice causes a 
lowered production of nitric oxide indicating that the substrate of nNOS, l-arginine, may 
be beneficial to cardiac and skeletal muscle function in mdx mice.  Oral l-arginine (5 
mg/g bw) improved cardiac contractility, coronary flow and reduced cardiac fibrosis 
(P<0.05) without improving skeletal muscle function or fibrosis.  In contrast, 10 mg/g bw 
l-arginine improved cardiac function and coronary flow (P<0.01), despite also elevating 
cardiac collagen. This increment in collagen was prevented by co-administration of 
prednisone.   
 
The experiments described in this dissertation reveal for the first time that 
pharmacological treatments in mdx mice can improve cardiac structure and function.  
Further elucidation of the optimum time and doses of such treatments may result in future 
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